Serial No.: To be determined

Filed: Herewith

Page 3 of 8

Amendments to the Claims:

Please add claims 20-51 as follows:

- 20. (New) A biodegradable implant for placement in an eye, comprising: a steroid and a polylactic acid polyglycolic acid (PLGA) copolymer, wherein the steroid makes up between about 1 percent by weight and about 80 percent by weight of the biodegradable implant, and wherein the implant releases at least about 20% of the steroid within about 1 week when measured under infinite sink conditions in vitro.
- 21. (New) The implant of claim 20, wherein the steroid is dexamethasone.
- 22. (New) The implant of claim 21, wherein the dexamethasone makes up about 50 percent by weight of the implant.
- 23. (New) The implant of claim 20, wherein the steroid is located within a polylactic acid polyglycolic acid (PLGA) copolymer matrix.
- 24. (New) The implant of claim 20, wherein the implant releases at least about 50% of the dexamethasone within 2 weeks when measured under infinite sink conditions in vitro.
- 25. (New) The implant of claim 20, wherein the implant releases at least about 80% of the dexamethasone within about 3 weeks when measured under infinite sink conditions in vitro.

Serial No.: To be determined

Filed: Herewith

Page 4 of 8

- 26. (New) The implant of claim 20, wherein the implant is configured as a disc.
- 27. (New) The implant of claim 26, wherein the implant has a thickness of about 0.15 mm.
- 28. (New) The implant of claim 26, wherein the implant has a diameter of about 2.5 mm.
- 29. (New) The implant of claim 20, wherein the steroid is dexamethasone and makes up about 20% by weight of the implant.
- 30. (New) The implant of claim 20, wherein the implant is sized to be placed intrasclerally or intralammellary in an eye.
- 31. (New) The implant of claim 20, further comprising an additional different therapeutic agent selected from the group consisting of anti-inflammatory agents, anti-proliferative agents, anti-viral agents, and anti-bacterial agents.
- 32. (New) The implant of claim 20, further comprising 5-flurouracil mixed with the steroid and the PLGA copolymer.
- 33. (New) The implant of claim 20, further comprising ciprofloxacin mixed with the steroid and the PLGA copolymer.
- 34. (New) The implant of claim 20 formed by an extrusion process.

Serial No.: To be determined

Filed: Herewith

Page 5 of 8

- 35. (New) The implant of claim 20, further comprising a release modifier.
- 36. (New) The implant of claim 20, which includes no release modifier.
- 37. (New) A biodegradable implant for placement in an eye, comprising: a mixture of an anti-inflammatory agent and a biodegradable polymer, wherein the anti-inflammatory agent makes up between about 1 percent by weight and about 80 percent by weight of the biodegradable implant, and wherein the implant releases the anti-inflammatory agent at a substantially constant rate for at least about three weeks as the implant degrades.
- 38. (New) The implant of claim 37, wherein the biodegradable polymer is a copolymer.
- 39. (New) The implant of claim 37, wherein the biodegradable polymer is a polylactic acid polyglycolic acid (PLGA) copolymer.
- 40. (New) The implant of claim 37, wherein the implant releases at least about 10% of the anti-inflammatory agent within about 3 days.
- 41. (New) The implant of claim 40, wherein the implant releases at least about 50% of the anti-inflammatory agent within about 2 weeks.

Serial No.: To be determined

Filed: Herewith

Page 6 of 8

- 42. (New) The implant of claim 41, wherein the release of the anti-inflammatory agent is measured under infinite sink conditions in vitro.
- 43. (New) The implant of claim 41, wherein the implant releases at least about 80% of the anti-inflammatory agent within about 3 weeks.
- 44. (New) The implant of claim 37, wherein the anti-inflammatory agent is a steroid.
- 45. (New) The implant of claim 44, wherein the steroid is dexamethasone.
- 46. (New) The implant of claim 37, wherein the implant is configured as a disc.
- 47. (New) The implant of claim 37, further comprising an additional different therapeutic agent selected from the group consisting of anti-inflammatory agents, anti-proliferative agents, anti-viral agents, and anti-bacterial agents.
- 48. (New) The implant of claim 37, wherein the anti-inflammatory agent is dexamethasone provided in an amount of about 50% by weight of the implant.
- 49. (New) The implant of claim 37, further comprising a release modifier mixed with the anti-inflammatory agent and the biodegradable polymer.

Serial No.: To be determined

Filed: Herewith

Page 7 of 8

- 50. (New) The implant of claim 37, which includes no release modifier.
- 51. (New) The implant of claim 37, wherein the mixture is an extruded mixture.